Kyntra Bio posts investor presentation highlighting FG-3246/FG-3180 Phase 2 program in prostate cancer
Reuters2026/08/13 20:23- Kyntra Bio highlighted Phase 2 enrollment for FG-3246 monotherapy in metastatic castration-resistant prostate cancer, paired with FG-3180 PET imaging.
- Interim Phase 2 analysis targeted for 4Q 2026, aimed at selecting an optimal Phase 3 dose based on efficacy, safety, pharmacokinetics.
- Roxadustat positioned as a Phase 3-ready U.S. program for anemia in lower-risk MDS with high transfusion burden, following FDA trial-design alignment.
- Phase 3 initiation for roxadustat targeted for 4Q 2026; costs for an internally run study excluded from cash runway projections.
- Cash runway projected into 2028; roxadustat has Orphan Drug Designation in MDS granted in December 2025.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The first major "exam" after the Cook era! Morgan Stanley: Apple's (AAPL.US) autumn launch event is the most important in ten years; the first foldable iPhone may spark a new wave of growth
Morgan Stanley analysts stated that Apple's upcoming "Surprise and Shine" autumn product launch event on September 9 may become the company's most important product release in nearly a decade.
For the first time in over a year, the open interest share of altcoins has surpassed that of bitcoin.
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Crypto prices
More
